相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Rapid Development of SARS-CoV-2 Spike Protein Receptor-Binding Domain Self-Assembled Nanoparticle Vaccine Candidates
Yin-Feng Kang et al.
ACS NANO (2021)
Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity
Erik Volz et al.
CELL (2021)
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Merryn Voysey et al.
LANCET (2021)
A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses
Tiong Kit Tan et al.
NATURE COMMUNICATIONS (2021)
Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity
Cyrielle Fougeroux et al.
NATURE COMMUNICATIONS (2021)
SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice
Jing-Hui Tian et al.
NATURE COMMUNICATIONS (2021)
Recombinant protein vaccines, a proven approach against coronavirus pandemics
Jeroen Pollet et al.
ADVANCED DRUG DELIVERY REVIEWS (2021)
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera
Daming Zhou et al.
CELL (2021)
Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19
Kathryn E. Stephenson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Detection of a SARS-CoV-2 variant of concern in South Africa
Houriiyah Tegally et al.
NATURE (2021)
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Nicholas G. Davies et al.
SCIENCE (2021)
Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques
Hyon-Xhi Tan et al.
NATURE COMMUNICATIONS (2021)
Induction of Potent and Durable Neutralizing Antibodies Against SARS-CoV-2 Using a Receptor Binding Domain-Based Immunogen
Vikram Srivastava et al.
FRONTIERS IN IMMUNOLOGY (2021)
Self-Assembling Nanoparticle Vaccines Displaying the Receptor Binding Domain of SARS-CoV-2 Elicit Robust Protective Immune Responses in Rhesus Monkeys
Heng Li et al.
BIOCONJUGATE CHEMISTRY (2021)
SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
Markus Hoffmann et al.
CELL (2021)
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials
Shilong Yang et al.
LANCET INFECTIOUS DISEASES (2021)
Adjuvanting a subunit COVID-19 vaccine to induce protective immunity
Prabhu S. Arunachalam et al.
NATURE (2021)
Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7
Nicholas G. Davies et al.
NATURE (2021)
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies
Delphine Planas et al.
NATURE MEDICINE (2021)
The success of SARS-CoV-2 vaccines and challenges ahead
Kanta Subbarao
CELL HOST & MICROBE (2021)
Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2
Shiyu Sun et al.
CELL RESEARCH (2021)
Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination
Emma C. Wall et al.
LANCET (2021)
Spike-antibody waning after second dose of BNT162b2 or ChAdOx1
Madhumita Shrotri et al.
LANCET (2021)
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine
Paul T. Heath et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques
Hannah A. D. King et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants
Amarendra Pegu et al.
SCIENCE (2021)
Covid-19: Pfizer vaccine's efficacy declined from 96% to 84% four months after second dose, company reports
Elisabeth Mahase
BMJ-BRITISH MEDICAL JOURNAL (2021)
Rapid generation of mouse model for emerging infectious disease with the case of severe COVID-19
Cheng-Pu Sun et al.
PLOS PATHOGENS (2021)
Durability of antibody response to vaccination and surrogate neutralization of emerging variants based on SARS-CoV-2 exposure history
Thomas W. McDade et al.
SCIENTIFIC REPORTS (2021)
Pathogenesis of SARS-CoV-2 in Transgenic Mice Expressing Human Angiotensin-Converting Enzyme 2
Ren-Di Jiang et al.
CELL (2020)
Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19
Yuwei Liu et al.
JOURNAL OF INFECTION (2020)
Self-Assembled Nanoparticles: Exciting Platforms for Vaccination
Jingdi Pan et al.
BIOTECHNOLOGY JOURNAL (2020)
Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies
Christopher O. Barnes et al.
CELL (2020)
Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus
Bette Korber et al.
CELL (2020)
Immune Phenotyping Based on the Neutrophil-to-Lymphocyte Ratio and IgG Level Predicts Disease Severity and Outcome for Patients With COVID-19
Bicheng Zhang et al.
FRONTIERS IN MOLECULAR BIOSCIENCES (2020)
Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology
Luca Piccoli et al.
CELL (2020)
Why and How Vaccines Work
Akiko Iwasaki et al.
CELL (2020)
A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity
Jingyun Yang et al.
NATURE (2020)
Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike
Lihong Liu et al.
NATURE (2020)
Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
Philip J. M. Brouwer et al.
SCIENCE (2020)
Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate
Sandhya Bangaru et al.
SCIENCE (2020)
Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses
Xiancai Ma et al.
IMMUNITY (2020)
Covid-19: FDA panel votes to approve Pfizer BioNTech vaccine
Janice Hopkins Tanne
BMJ-BRITISH MEDICAL JOURNAL (2020)
Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2
Alexandra C. Walls et al.
CELL (2020)
Potential Zika Vaccine: Encapsulated Nanocomplex Promotes Both TH1/TH2 Responses in Mice
Yan-Wei Wu et al.
ADVANCED THERAPEUTICS (2020)
Role of Multivalency and Antigenic Threshold in Generating Protective Antibody Responses
Mark K. Slifka et al.
FRONTIERS IN IMMUNOLOGY (2019)
Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection
Li Liu et al.
JCI INSIGHT (2019)
The origins of the vaccine cold chain and a glimpse of the future
John Lloyd et al.
VACCINE (2017)
Immunization with Recombinant TcdB-Encapsulated Nanocomplex Induces Protection against Clostridium difficile Challenge in a Mouse Model
Yi-Wen Liu et al.
FRONTIERS IN MICROBIOLOGY (2017)
Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
V. Stalin Raj et al.
NATURE (2013)
Development of amphiphilic γ-PGA-nanoparticle based tumor vaccine:: Potential of the nanoparticulate cytosolic protein delivery carrier
Tomoaki Yoshikawa et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination
David A. Zaharoff et al.
VACCINE (2007)
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
WH Li et al.
NATURE (2003)
Type 1 type 2 immunity in infectious diseases
B Spellberg et al.
CLINICAL INFECTIOUS DISEASES (2001)